Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors
- Conditions
- Advanced Solid TumorLymphoma
- Interventions
- Drug: T-1301 Capsules
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Taivex Therapeutics Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT05156203
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei City, Taiwan
🇨🇳ChangGung Memorial Hospital, Linkou, Taoyuan City, Taiwan
Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: T-1201 Injection 100 mg Kit
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Taivex Therapeutics Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT04866641
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors
- Conditions
- Advanced Refractory Solid Tumors
- Interventions
- Drug: T-1101 (Tosylate)
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Taivex Therapeutics Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT04685473
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
- Conditions
- Advanced Refractory Solid Tumors
- Interventions
- Drug: T-1101 (Tosylate)
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Taivex Therapeutics Corporation
- Target Recruit Count
- 3
- Registration Number
- NCT03349073
- Locations
- 🇨🇳
China Medical University Hospital, Taichung City, Taiwan
🇨🇳National Cheng Kung University (NCKU) Hospital, Tainan, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan
Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
- Conditions
- Advanced Refractory Solid Tumors
- Interventions
- Drug: T-1101 (Tosylate)
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Taivex Therapeutics Corporation
- Target Recruit Count
- 21
- Registration Number
- NCT03195764
- Locations
- 🇨🇳
China Medical University Hospital, Taichung City 404327, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Taipei Medical University Hospital, Taipei, Taiwan